CN114341171A - 识别p53中的r175h或y220c突变的t细胞受体 - Google Patents

识别p53中的r175h或y220c突变的t细胞受体 Download PDF

Info

Publication number
CN114341171A
CN114341171A CN202080047882.0A CN202080047882A CN114341171A CN 114341171 A CN114341171 A CN 114341171A CN 202080047882 A CN202080047882 A CN 202080047882A CN 114341171 A CN114341171 A CN 114341171A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
polypeptide chain
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080047882.0A
Other languages
English (en)
Chinese (zh)
Inventor
德鲁·C·丹尼格尔
帕里萨·马勒克扎德
史蒂文·A·罗森伯格
安娜·帕塞托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN114341171A publication Critical patent/CN114341171A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
CN202080047882.0A 2019-06-27 2020-06-26 识别p53中的r175h或y220c突变的t细胞受体 Pending CN114341171A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867619P 2019-06-27 2019-06-27
US62/867,619 2019-06-27
PCT/US2020/039785 WO2020264269A1 (en) 2019-06-27 2020-06-26 T cell receptors recognizing r175h or y220c mutation in p53

Publications (1)

Publication Number Publication Date
CN114341171A true CN114341171A (zh) 2022-04-12

Family

ID=71662353

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080047882.0A Pending CN114341171A (zh) 2019-06-27 2020-06-26 识别p53中的r175h或y220c突变的t细胞受体

Country Status (11)

Country Link
US (1) US12479902B2 (https=)
EP (1) EP3990481A1 (https=)
JP (2) JP7635165B2 (https=)
KR (1) KR20220047969A (https=)
CN (1) CN114341171A (https=)
AU (1) AU2020308004B2 (https=)
BR (1) BR112021026408A2 (https=)
CA (1) CA3144070A1 (https=)
MX (1) MX2021015877A (https=)
TW (2) TWI908730B (https=)
WO (1) WO2020264269A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210189336A1 (en) * 2017-10-18 2021-06-24 Vivia Biotech, S.L. Bite-activated car-t cells
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20240209058A1 (en) * 2021-04-30 2024-06-27 Regents Of The University Of Minnesota Mesothelin-specific T cell Receptors and Methods of Using Same
AU2022271195A1 (en) * 2021-05-03 2023-11-02 Bluesphere Bio, Inc. T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
WO2022236050A1 (en) * 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
WO2024076692A1 (en) * 2022-10-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as p53 acetylators
WO2024163371A1 (en) * 2023-01-30 2024-08-08 Fred Hutchinson Cancer Center Binding proteins specific for mutant p53 and uses thereof
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2024220520A2 (en) * 2023-04-21 2024-10-24 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067242A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53
WO2019067243A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN107748893A (zh) * 2017-09-29 2018-03-02 阿里巴巴集团控股有限公司 提升车辆定损图像识别结果的方法、装置及服务器
WO2022236050A1 (en) 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067242A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53
WO2019067243A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DREW C DENIGER等: "T-cell Responses to TP53 \"Hotspot\" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers", CLIN CANCER RES ., vol. 24, no. 22, pages 5562 - 5573 *
WINIFRED LO等: "Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer", CANCER IMMUNOL RES, vol. 7, no. 4, pages 534 - 543, XP055730133, DOI: 10.1158/2326-6066.CIR-18-0686 *

Also Published As

Publication number Publication date
CA3144070A1 (en) 2020-12-30
BR112021026408A2 (pt) 2022-02-08
US12479902B2 (en) 2025-11-25
JP2022538148A (ja) 2022-08-31
TW202525841A (zh) 2025-07-01
WO2020264269A1 (en) 2020-12-30
US20220332785A1 (en) 2022-10-20
TW202108609A (zh) 2021-03-01
TWI908730B (zh) 2025-12-21
MX2021015877A (es) 2022-04-18
JP2025081413A (ja) 2025-05-27
EP3990481A1 (en) 2022-05-04
JP7635165B2 (ja) 2025-02-25
AU2020308004A1 (en) 2022-02-03
AU2020308004B2 (en) 2026-03-19
KR20220047969A (ko) 2022-04-19

Similar Documents

Publication Publication Date Title
AU2022203507B2 (en) Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
AU2021200833B2 (en) T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
AU2018378200B2 (en) HLA class I-restricted T cell receptors against mutated RAS
EP3688027B1 (en) T cell receptors recognizing mutated p53
CN109790211B (zh) 抗kras-g12d t细胞受体
KR20200065026A (ko) P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
CA3021898A1 (en) Anti-kk-lc-1 t cell receptors
CN115279784A (zh) 针对含有g12d突变的ras的hla i类限制性t细胞受体
CN116710111A (zh) 针对含有g13d突变的ras的hla ii类限制性dq t细胞受体
RU2830061C2 (ru) T-клеточные рецепторы, распознающие мутацию r175h или y220c в p53
CN116472050A (zh) 识别p53中r273c或y220c突变的t细胞受体
CA3032870C (en) Anti-kras-g12d t cell receptors
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
HK40031140B (en) T cell receptors recognizing mutated p53
HK40031140A (en) T cell receptors recognizing mutated p53
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination